Modeling-Based Approach Towards Quality by Design for the Ibipinabant API Step
- 3 April 2012
- journal article
- review article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 16 (4) , 567-576
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- An Example of Utilizing Mechanistic and Empirical Modeling in Quality by DesignJournal of Pharmaceutical Innovation, 2010
- Application of Quality by Design Principles for the Definition of a Robust Crystallization Process for Casopitant MesylateOrganic Process Research & Development, 2010
- Modeling of Pan Coating Processes: Prediction of Tablet Content Uniformity and Determination of Critical Process ParametersJournal of Pharmaceutical Sciences, 2010
- PQLI Design SpaceJournal of Pharmaceutical Innovation, 2008
- PQLI Key Topics - Criticality, Design Space, and Control StrategyJournal of Pharmaceutical Innovation, 2008
- The Use of Routine Process Capability for the Determination of Process Parameter Criticality in Small-molecule API SynthesisJournal of Pharmaceutical Innovation, 2008
- API Quality by Design Example from the Torcetrapib Manufacturing ProcessJournal of Pharmaceutical Innovation, 2007
- Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicityBioorganic & Medicinal Chemistry Letters, 2005
- Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB1 Cannabinoid Receptor AntagonistsJournal of Medicinal Chemistry, 2003